Treatment of pyoderma gangrenosum with apremilast monotherapy

Zachary A Bordeaux; Shawn G Kwatra; Cameron E West

doi:10.1016/j.jdcr.2022.10.001

Treatment of pyoderma gangrenosum with apremilast monotherapy

JAAD Case Rep. 2022 Oct 11:30:8-10. doi: 10.1016/j.jdcr.2022.10.001. eCollection 2022 Dec.

Authors

Zachary A Bordeaux¹, Shawn G Kwatra^{1

2}, Cameron E West^{3

4}

Affiliations

¹ Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
² Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
³ Genzada Pharmaceuticals, Hutchinson, Kansas.
⁴ US Dermatology Partners, Wichita, Kansas.

No abstract available

Keywords: IL, Interleukin; PDE4, phosphodiesterase 4; PG, Pyoderma gangrenosum; TNF, Tumor necrosis factor; cAMP, cyclic adenosine monophosphate; case reports; cytokines; immunomodulators; neutrophils/neutrophilic; pyoderma gangrenosum; therapeutics.

Publication types

Case Reports